SynthesisWomen's health (London, England)
Twenty-first century oocyte cryopreservation-in vitro maturation of immature oocytes from ovarian tissue cryopreservation in cancer patients: A systematic review.
Synthesis in Women's health (London, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- The use of ex-vivo in-vitro maturation of ovarian tissues oocytes (OTO-IVM) for fertility preservation in gynaecologic cancers.Gynecologic oncology reports · 2026Article
- Review
- Surgical approaches to fertility preservation in the cancer patient: current and future directions.Frontiers in endocrinology · 2026Review
- [Ovarian tissue cryopreservation and transplantation: a review of clinical progress in fertility preservation].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Advances, Mechanisms, and Clinical Perspectives for the In Vitro Maturation of Human Oocytes.International journal of molecular sciences · 2025Review
- Clinical outcomes over 12 years: a comparative analysis of oocyte cryopreservation from controlled ovarian stimulation and in vitro maturation retrieved from ovarian tissue.Journal of ovarian research · 2025Article
- Risk Assessment and Fertility Counseling for Hereditary Gynecological Cancer Syndromes.Cancer medicine · 2025Review
- REPRODUCTIVE HEALTH IN TRANS AND GENDER-DIVERSE PATIENTS: Gonadal tissue cryopreservation in transgender and gender-diverse people.Reproduction (Cambridge, England) · 2024Review
- Current State and Challenges of Tissue and Organ Cryopreservation in Biobanking.International journal of molecular sciences · 2024Review
- Exploring the Frontiers of Ovarian Tissue Cryopreservation: A Review.Journal of clinical medicine · 2024Review
- Restoring Ovarian Fertility and Hormone Function: Recent Advancements, Ongoing Efforts and Future Applications.Journal of the Endocrine Society · 2024Review
- Breast Cancer and Fertility Preservation in Young Female Patients: A Systematic Review of the Literature.Clinics and practice · 2023Review
- Risk reduction for small cell cancer of the ovary, hypercalcemic type in prepubertal patient: A clinical and bioethical perspective.Gynecologic oncology reports · 2023Article
- Fertility preservation in pediatric leukemia and lymphoma: A report from the Children's Oncology Group.Pediatric blood & cancer · 2023Article
- The spectrum ofFrontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOur review aimed to consolidate the latest update on the application of in vitro maturation among immature oocyte harvest in combination with ovarian tissue cryopreservation known as ovarian tissue oocyte-in vitro maturation.
methodsA thorough search for relevant studies was conducted via PubMed, Google Scholar, EMBASE, and clinical.gov databases up to December 2020. The primary outcome was the oocyte maturation rate, which measured the number of immature oocytes (geminal vesicle stage) that progressed to mature oocytes (meiosis II stage) following in vitro maturation. The secondary outcomes were the fertilization rate following intracytoplasmic sperm injection/in vitro fertilization of these oocytes for the embryo cryopreservation cohort. Our review included pre-pubertal girls and women with cancer who underwent ovarian tissue oocyte-in vitro maturation as fertility preservation.
resultsThe primary search identified 207 studies. Twelve manuscripts were selected for inclusion in our review following duplication assessment, title and abstract screening, and full-text evaluation tailored to our inclusion criteria. All the population belonged to a cancer group and underwent concurrent ovarian tissue oocyte-in vitro maturation. A total of 5724 immature oocytes were obtained following ovarian tissue cryopreservation. Approximately 33.84% of the immature oocytes successfully matured via in vitro maturation, which were cryopreserved as oocytes or fertilized as embryos and subsequently stored for future use.
conclusionOur review proposed the potential application of ovarian tissue oocyte-in vitro maturation in increasing the number of mature oocytes. The acceptable improvement in oocyte maturation rate following in vitro maturation indicates that improving oocyte outcomes is an excellent cost-effective strategy for fertility preservation among women with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.